Janssen Alzheimer Immunotherapy
Records under this name other than patents Janssen Alzheimer Immunotherapy holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Janssen Alzheimer Immunotherapy
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,625,560 | Humanized Antibodies That Recognize Beta Amyloid Peptide Formerly held In force · High confidence | In force | High confidence | |
| US 8,784,810 | Treatment of amyloidogenic diseases Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,635,473 | Anti a Beta Antibody Formulation Formerly held In force · High confidence | In force | High confidence | |
| US 8,506,959 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease Formerly held In force · High confidence | In force | High confidence | |
| US 9,272,030 | Use of Tau to Monitor Immunotherapy Formerly held In force · High confidence | In force | High confidence | |
| US 9,644,025 | Immunotherapy Regimes Dependent on Apoe Status Formerly held In force · High confidence | In force | High confidence | |
| US 7,820,799 | Methods of Purifying FC Region Containing Proteins Term ended Ended no later than Oct 25, 2026 · Medium confidence | Term ended | Ended no later than Oct 25, 2026 | Medium confidence |
| US 7,727,957 | Treatment and Delay of Outset of Parkinson's Disease Term ended Term ended Aug 14, 2025 · High confidence | Term ended | Term ended Aug 14, 2025 | High confidence |
| US 8,357,781 | Neuroactive Fragments of App Lapsed on the fee record Ended Jan 22, 2025 · High confidence | Lapsed on the fee record | Ended Jan 22, 2025 | High confidence |
| US 9,034,337 | Treatment and Delay of Outset of Synucleinopathic and Amyloidogenic Disease Formerly held Term ended Term ended Jan 22, 2025 · Medium confidence | Term ended | Term ended Jan 22, 2025 | Medium confidence |